Clinical Trial Detail

NCT ID NCT02236572
Title Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Yale University
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus

Age Groups: adult

Additional content available in CKB BOOST